Position in ANNX
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$122,988
+$62,748 QoQ
Shares Held
22,200
+85.0% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.14%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ANNX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Cygnus Capital Advisors, LLC holds $1,252,849 across 18 Biotechnology names. ANNX ranks #4 (9.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZYME |
Zymeworks Inc.
|
8,197 | $205,252 | |
| 2 | SION |
Sionna Therapeutics, Inc.
|
3,800 | $152,342 | |
| 3 | IMNM |
Immunome Inc.
|
6,880 | $150,465 | |
| 4 | ANNX |
Annexon, Inc.
This page
|
22,200 | $122,988 | |
| 5 | EWTX |
Edgewise Therapeutics, Inc.
|
3,427 | $107,950 | |
| 6 | CMPX |
Compass Therapeutics, Inc.
|
18,000 | $95,220 | |
| 7 | RANI |
Rani Therapeutics Holdings, Inc.
|
115,649 | $85,002 | |
| 8 | LIMN |
Liminatus Pharma, Inc.
|
350,000 | $60,200 |
All Filings in ANNX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $122,988 | 22,200 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $60,240 | 12,000 | Shares | Sole | 2026-05-12 | |
| No filing history on record for this holder in this stock. | ||||||